A Phase IIa Placebo-Controlled, Double-Blind Randomized Withdrawal Study to Evaluate the Safety and Efficacy of CNV1014802 in Patients With Trigeminal Neuralgia

Trial Profile

A Phase IIa Placebo-Controlled, Double-Blind Randomized Withdrawal Study to Evaluate the Safety and Efficacy of CNV1014802 in Patients With Trigeminal Neuralgia

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Sep 2017

At a glance

  • Drugs Raxatrigine (Primary)
  • Indications Trigeminal neuralgia
  • Focus Therapeutic Use
  • Sponsors Convergence Pharmaceuticals
  • Most Recent Events

    • 29 Oct 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 16 Jun 2014 Results published in the Convergence Pharmaceuticals Media Release.
    • 28 Jan 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top